By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Biotechnology have been published. According to news reporting originating from Ljubljana, Slovenia, by NewsRx correspondents, research stated, "Almost all of the 200 or so approved biopharmaceuticals have been produced in one of three host systems: the bacterium Escherichia coli, yeasts (Saccharomyces cerevisiae, Pichia pastoris) and mammalian cells. We describe the most widely used methods for the expression of recombinant proteins in the cytoplasm or periplasm of E. coli, as well as strategies for secreting the product to the growth medium."
Our news editors obtained a quote from the research from Jozef Stefan Institute, "Recombinant expression in E. coli influences the cell physiology and triggers a stress response, which has to be considered in process development. Increased expression of a functional protein can be achieved by optimizing the gene, plasmid, host cell, and fermentation process. Relevant properties of two yeast expression systems, S. cerevisiae and P. pastoris, are summarized. Optimization of expression in S. cerevisiae has focused mainly on increasing the secretion, which is otherwise limiting. P. pastoris was recently approved as a host for biopharmaceutical production for the first time. It enables high-level protein production and secretion. Additionally, genetic engineering has resulted in its ability to produce recombinant proteins with humanized glycosylation patterns. Several mammalian cell lines of either rodent or human origin are also used in biopharmaceutical production. Optimization of their expression has focused on clonal selection, interference with epigenetic factors and genetic engineering. Systemic optimization approaches are applied to all cell expression systems. They feature parallel high-throughput techniques, such as DNA microarray, next-generation sequencing and proteomics, and enable simultaneous monitoring of multiple parameters."
According to the news editors, the research concluded: "Systemic approaches, together with technological advances such as disposable bioreactors and microbioreactors, are expected to lead to increased quality and quantity of biopharmaceuticals, as well as to reduced product development times."
For more information on this research see: Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. Journal of Industrial Microbiology & Biotechnology, 2013;40(3-4):257-74. Journal of Industrial Microbiology & Biotechnology can be contacted at: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. (Springer - www.springer.com; Journal of Industrial Microbiology & Biotechnology - www.springerlink.com/content/1367-5435/)
The news editors report that additional information may be obtained by contacting A. Berlec, Dept. of Biotechnology, Joef Stefan Institute, Jamova 39, Ljubljana, Slovenia (see also technology.html">Biotechnology).
Publisher contact information for the Journal of Industrial Microbiology & Biotechnology is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA.
Keywords for this news article include: Biotechnology, Drugs, Europe, Therapy, Slovenia, Ljubljana, Escherichia coli, Biopharmaceuticals, Enterobacteriaceae, Genetic Engineering, Gram Negative Bacteria.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC